AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, covers production of five biopharmaceutical products with at least 35 batches annually, supporting global supply chain reliability. The agreement includes process transfer, scale-up, regulatory validation, and commercial production to meet approvals from EMA, FDA, MHRA, and PMDA. The Yokohama site, opening in 2027, will enhance AGC's global single-use bioproduction capacity and strengthen Japan's strategic role in resilient biopharma supply chains amid geopolitical risks.
XRP is nearing a key technical point where it needs to close above $1.53 on a four-hour chart to confirm a breakout. The token briefly hit $1.55 but failed to sustain above $1.53, leaving the breakout unconfirmed. If confirmed, the next target is $1....
Ten years ago, Intel's market value was about 28 times greater than AMD's. Today, AMD's market value has grown significantly and is now approximately 60% higher than Intel's. This dramatic shift highlights AMD's rise in the semiconductor industry and...
OPEC+ decided to keep oil production targets unchanged for November, reflecting ongoing export disruptions caused by the US-Israeli conflict with Iran. Despite rising flows through the Strait of Hormuz, Gulf producers are pumping below their quotas, ...
Tokenized stocks on the Solana blockchain have reached $12.4 billion in decentralized exchange (DEX) trading volume in 2026, with Raydium leading at $6.1 billion. Solana dominates global on-chain equity DEX trading, capturing about 95% during peak pe...
Bitcoin surged past $84,000 on October 2, marking a 43% gain in Q3 2026 and outperforming gold and many stocks. This rally is supported by a 60% increase in Bitcoin futures open interest and recent SEC proposals allowing broader crypto custody option...
